Suriclone: a new anxiolytic drug.

Abstract

Suriclone, a new psychotherapeutic agent chemically unrelated to benzodiazepines or phenothiazines was assessed in a single-blind dose-ranging study to determine its efficacy and safety in out-patients with generalized anxiety disorder. Suriclone was an effective anxiolytic drug at a dose range between 1.2 mg. and 3.6 mg. per day. The drug, when effective, has a duration of action between 6 and 8 hours. There was no evidence of a rebound phenomenon. There was, however, a rapid return to pre-treatment level of anxiety. Side effects were few, mild and transient. This new molecule may herald an advance in the treatment of these disorders and should be investigated more fully.

• Authors: Y D Lapierre, K L Oyewumi
• Journal: Progress in neuro-psychopharmacology & biological psychiatry (Prog Neuropsychopharmacol Biol Psychiatry) Vol. 7 Issue 4-6 Pg. 805-7 ( 1983) ISSN: 0278-5846 [Print] England
• PMID: 6141620 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Anti-Anxiety Agents
• Naphthyridines
• Piperazines
• Sulfur Compounds
• suriclone

Topics

• Adult
• Anti-Anxiety Agents (therapeutic use)
• Anxiety Disorders (drug therapy, psychology)
• Clinical Trials as Topic
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Naphthyridines
• Piperazines (therapeutic use)
• Sulfur Compounds